Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease? Implications for Therapeutic Blockade of the Renin-Angiotensin System

Circulation

Volumn 109, Issue 1, 2004, Pages 8-13

  Lévy, Bernard I ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b INSERM   (France)

Author keywords

Angiotensin; Cardiovascular diseases; Hypertrophy; Receptors

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; TRANDOLAPRIL; VALSARTAN;

APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HEART MUSCLE CELL; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM;

EID: 0347988111     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000096609.73772.C5     Document Type: Review

References (54)

1. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999:33: 613-621.
2. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-1191.
3. Siragy HM. The role of the AT2 in hypertension. Am J Hypertens. 2000;13:62S-67S.
4. Carey RM, Jin XH, Siragy HM, et al. Role of the angiotensin AT2 in blood pressure regulation and therapeutic implications. Am J Hypertens. 2001;14:98S-102S.
5. Miura S, Karnik SS. Ligand-independent signals from angiotensin II receptor induce apoptosis. EMBO J. 2000;19:4026-4035.
6. Henrion D, Kubis N, Levy B, et al. Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150-1157.
7. Lévy B, Benessiano IJ, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II 11 on the rat vascular structure. J Clin Invest. 1996;98:418-425.
8. Maeso R, Navarro-Cid J, Munoz-Garcia R, et al. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats: role of nitric oxide and angiotensin II type 2 receptors. Hypertension. 1996;28:967-972.
9. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res. 2001;88;654-658.
10. Inagami T, Senbonmatsu T. Dual effects of angiotensin II type 2 receptor on cardiovascular hypertrophy. Trends Cardiovasc Med. 2001;11: 324-328.
11. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996; 27:760-765.
12. Hein L, Barsh GS, Pratt RE, et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995; 377:744-747.
13. Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748-750.
14. Akishita M, Yamada H, Dzau VJ, et al. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun. 1999;261:345-349.
15. Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-35.
16. Touyz RM, Endemann D, He G, et al. Role of AT2 in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension. 1999;33:366-372.
17. Matrougui K, Lévy BI, Henrion D, et al. Tissue angiotensin II and endothelin-I modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats. Br J Pharmacol. 2000; 130:521-526.
18. Hayashi K, Suzuki H, Saruta T. Segmental differences in angiotensin receptor subtypes in interlobular artery of hydronephrotic rat kidneys. Am J Physiol. 1993;265:F881-F885.
19. Endo Y, Arima S, Yaoita H, et al. Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats. J Vasc Res. 1998;35:421-427.
20. Siragy HM, Inagami T, Ichiki T, et al. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Nat Acad Sci U S A. 1999;96:6506-6510.
21. Cox BE, Word RA, Rosenfeld CR, et al. Angiotensin II receptor characteristics and subtype expression in uterine arteries and myometrium during pregnancy. J Clin Endocrinol Metab. 1996;81:49-58.
22. Zwart AS, Davis EA, Widdop RE, et al. Modulation of AT1 receptor-mediated contraction of rat uterine artery by AT2. Br J Pharmacol. 1998;125:1429-1436.
23. Widdop RE, Matrougui K, Levy BI, et al. AT2-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002; 40:516-520.
24. Diep QN, Li JS, Schiffrin EL, et al. In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension. 1999;34:617-624.
25. Cao Z, Dean R, Wu L, et al. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 1999; 34:408-414.
26. Senbonmatsu T, Ichihara S, Price E, et al. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000;106:R25-R29.
27. Ichihara S, Senbonmatsu T, Price E, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001;104:346-351.
28. Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT2 expression and signalling. Physiol Genom. 2000;2:13-20.
29. Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodelling after aortic banding in mice. Circulation. 2000;102:1684-1689.
30. Otsuka S, Sugano M. Makino N. et al. Interaction of mRNAs for angiotensin II type I and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension. 1998;32:467-472.
31. Schneider MD, Lorell BH. AT2, judgment day: which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation. 2001;104; 247-248.
32. Filippatos G, Tilak M, Pinillos H, et al. Regulation of apoptosis by angiotensin II in the heart and lungs. Int J Mol Med. 2001;7:273-280.
33. Gobe G, Browning J, Howard T, et al. Apoptosis occurs in endothelial cells during hypertension-induced microvascular rarefaction. J Struct Biol. 1997;118:63-72.
34. Kubis N, Richer C, Domergue V, et al. Role of microvascular rarefaction in the increased arterial pressure in mice lacking the endothelial nitric oxide synthase gene (eNOS3pt-/-). J Hypertens. 2002;20:1581-1587.
35. Goldenberg I, Grossman E, Jacobson KA, et al. Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2. J Hypertens. 2001;19:1681-1689.
36. Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol. 2002;283: F173-F180.
37. Bhaskaran M, Reddy K, Radhakrishanan N, et al. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol. 2003;284:F955-F965.
38. Yamada T, Horiuchi M, Dzau VJ, et al. Angiotensin II type 2 receptor mediates programmed cell death. Proc Nat Acad Sci USA. 1996;93: 156-160.
39. Cao Z, Kelly DJ, Cox A, et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000:58:2437-2451.
40. Marchand EL, Der Sarkissian S, Hamet P, et al. Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats. Circ Res. 2003;92:777-784.
41. Sugino H, Ozono R, Kurisu S, et al. Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension. 2001;37:1394-1398.
42. Moudgil R, Musat-Marcu S, Xu Y, et al. Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade. Can J Cardiol. 2002;18:1107-1116.
43. Bascands JL, Girolami JP, Troly M, et al. Angiotensin II induces phenotype-dependent apoptosis in vascular smooth muscle cells. Hypertension. 2001;38:1294-1299.
44. Tea B-S, Der Sarkissian S, Touyz RM, et al. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension. 2000;35: 1069-1073.
45. Silvestre J-S, Tamarat R, Senbonmatsu T, et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2002;90:1072-1079.
46. Fabre JE, Rivard A, Magner M, et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
47. Silvestre JS, Kamsu-Kom N, Clergue M, et al. Very-low dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther. 2002:303: 1038-1043.
48. Silvestre J-S, Bergaya S, Tamarat R, et al. Proangiogenic effect of angiotensin-converting enzyme is mediated by the bradykinin B2 receptor pathway. Circ Res. 2001;89:678-683.
49. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
50. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752-760.
51. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
52. Emanueli C, Salis MB, Stacca T, et al. Targeting kinin BI receptor for therapeutic neovascularization. Circulation. 2002;105:360-366.
53. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349;1893-1906.
54. Nakao N, Yoshimura A, Morita H. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-124.